Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare (3 minute read)

TLDR AI News

Summary

Anthropic is launching an internal AI drug discovery program to develop treatments for neglected diseases, aiming to improve its AI tools for drugmakers and join tech giants in the healthcare market.

Anthropic is starting an internal drug discovery program to develop AI tools designed for drugmakers. The company will focus on discovering treatments for neglected diseases that traditional biopharmaceutical companies wouldn't consider attractive targets. It is unclear what Anthropic will do if it finds any promising drug candidates.
Original Article
View Cached Full Text

Cached at: 07/01/26, 05:19 PM

# Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare Source: [https://www.cnbc.com/2026/06/30/anthropic-launches-ai-drug-discovery-program-claude-science.html](https://www.cnbc.com/2026/06/30/anthropic-launches-ai-drug-discovery-program-claude-science.html) CEO of Anthropic Dario Amodei attends a working lunch with G7 leaders, G7 outreach partners and global tech CEOs on innovation and AI, during the G7 Summit on June 17, 2026, in Évian\-les\-Bains, France\. Anna Moneymaker \| Getty Images News \| Getty Images Anthropic is starting an internal drug discovery program as part of an effort to develop artificial intelligence tools designed for drugmakers, becoming the latest company to try and crack the healthcare market\. At an event in San Francisco on Tuesday, Anthropic's life sciences head Eric Kauderer\-Abrams said the company will focus on discovering treatments for "neglected" diseases that traditional biopharmaceutical companies wouldn't consider attractive targets\. "We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you," Kauderer\-Abrams said\. "We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs\." Kauderer\-Abrams didn't say what Anthropic would do if it finds any promising drug candidates\. Traditional biopharmaceutical companies would typically test them in clinical trials\. An Anthropic spokesperson told CNBC that as a public benefit company, "we can choose programs on patient benefit, including work the commercial market overlooks\." "We're at the start of this, and we'll share more as the work progresses\." the spokesperson said\. Tech giants have long taken aim at healthcare, though with mixed results\.[Alphabet](https://www.cnbc.com/quotes/GOOG/)and[Apple](https://www.cnbc.com/quotes/AAPL/)have jumped into the market in various ways, and[Amazon](https://www.cnbc.com/quotes/AMZN/)has built a business in healthcare through its acquisitions of One Medical and PillPack, now housed in a division called[Amazon Health Services](https://www.cnbc.com/2025/06/13/amazon-reorganizes-its-health-care-business-after-executive-departures.html)\. Kauderer\-Abrams and other Anthropic leaders positioned Anthropic's effort as a way to work alongside the drugmakers it's trying to court for its new Claude Science product\. Jonah Cool, Anthropic's head of life sciences partnerships, said Anthropic's goal is to focus on neglected diseases as it creates and sells AI tools for life sciences companies\. **WATCH:**[Why OpenAI and Anthropic may be rushing to IPO](https://www.cnbc.com/video/2026/06/25/why-openai-and-anthropic-may-be-rushing-to-ipo-amid-fears-of-ai-premium-fading.html) ![Why OpenAI and Anthropic may be rushing to IPO amid fears of AI premium fading](https://image.cnbcfm.com/api/v1/image/108326909-17824032361782403233-46767192115-1080pnbcnews.jpg?v=1782403235&w=750&h=422&vtcrop=y)

Similar Articles

Anthropic

Reddit r/singularity

Anthropic, the AI safety and research company, is in the news.

Ahead of its IPO, Anthropic’s Daniela Amodei shrugs off doubts about AI’s returns

TechCrunch AI

Anthropic is moving toward a public IPO filing after raising $65 billion at a $965 billion valuation, with co-founder Daniela Amodei citing the need for capital to train frontier models and serve inference at scale. The company reported $47 billion in annualized revenue as of May 2026, and has partnered with xAI for $1.25 billion per month in compute capacity rather than building its own data centers.